ZA201007880B - Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant - Google Patents

Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant

Info

Publication number
ZA201007880B
ZA201007880B ZA2010/07880A ZA201007880A ZA201007880B ZA 201007880 B ZA201007880 B ZA 201007880B ZA 2010/07880 A ZA2010/07880 A ZA 2010/07880A ZA 201007880 A ZA201007880 A ZA 201007880A ZA 201007880 B ZA201007880 B ZA 201007880B
Authority
ZA
South Africa
Prior art keywords
expression vector
vector encoding
immunological adjuvant
alphavirus replicase
encoding alphavirus
Prior art date
Application number
ZA2010/07880A
Other languages
English (en)
Inventor
Kaja Kiiver
Rein Sikut
Urve Toots
Tarmo Molder
Andres Mannik
Mart Ustav
Katrin Kaldma
Original Assignee
Fit Biotech Oyj Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fit Biotech Oyj Plc filed Critical Fit Biotech Oyj Plc
Publication of ZA201007880B publication Critical patent/ZA201007880B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2010/07880A 2008-05-23 2010-11-03 Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant ZA201007880B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7189808P 2008-05-23 2008-05-23
PCT/EP2009/056240 WO2009141434A1 (en) 2008-05-23 2009-05-22 Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant

Publications (1)

Publication Number Publication Date
ZA201007880B true ZA201007880B (en) 2012-02-29

Family

ID=40910781

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/07880A ZA201007880B (en) 2008-05-23 2010-11-03 Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant

Country Status (15)

Country Link
US (1) US9474800B2 (enExample)
EP (1) EP2296702A1 (enExample)
JP (1) JP5663474B2 (enExample)
KR (1) KR20110044836A (enExample)
CN (1) CN102083463B (enExample)
AU (1) AU2009248735B2 (enExample)
BR (1) BRPI0913045A2 (enExample)
CA (1) CA2724570A1 (enExample)
IL (1) IL209077A0 (enExample)
MX (1) MX2010012587A (enExample)
NZ (1) NZ589495A (enExample)
RU (1) RU2010152562A (enExample)
SG (1) SG191600A1 (enExample)
WO (1) WO2009141434A1 (enExample)
ZA (1) ZA201007880B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220119D0 (en) * 2012-11-08 2012-12-26 Univ Cork Vector
CN111304201B (zh) * 2020-02-21 2022-10-21 华南农业大学 一种降低乙型脑炎脑病毒感染的siRNA及其应用
JP2023517644A (ja) * 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
US12178921B2 (en) 2020-08-14 2024-12-31 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
CN113846113B (zh) * 2021-09-09 2022-09-13 臻赫医药(杭州)有限公司 一种有限自我复制mRNA分子系统、制备方法及应用
JP2025504364A (ja) * 2022-01-08 2025-02-12 カロジェン コーポレイション 慢性ｂ型肝炎感染症を処置または防止するための複数抗原治療ワクチン
KR20240049429A (ko) 2022-10-08 2024-04-16 최주언 황금비율 계량컵

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684136A (en) * 1992-05-18 1997-11-04 Genentech, Inc. Chimeric hepatocyte growth factor (HGF) ligand variants
SE9401091D0 (sv) * 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) * 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
JP2002521461A (ja) * 1998-07-29 2002-07-16 インビトロゲン・コーポレーション Ｒｎａウイルスを用いる組換えタンパク質の調節発現
EP1226238A2 (en) * 1999-10-27 2002-07-31 Cytos Biotechnology AG Method for creating divergent populations of nucleic acid molecules and proteins
WO2002057316A1 (en) * 2000-12-28 2002-07-25 Kirin Beer Kabushiki Kaisha Novel monoclonal antibody
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
US20060251620A1 (en) * 2002-08-22 2006-11-09 Lidia Ivanova Inducible alphaviral/orip based gene expression system
ES2222095B1 (es) * 2003-07-02 2005-11-16 Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Inia Virus adn recombinantes que comprenden un adn complementario de un replicon de un virus arn y sus aplicaciones.
AU2005327198B2 (en) * 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
AU2007342333B2 (en) * 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
WO2008065225A2 (es) * 2006-11-28 2008-06-05 Proyecto De Biomedicina Cima, S.L. Vector viral y sus aplicaciones
WO2008119827A1 (en) * 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs

Also Published As

Publication number Publication date
JP2011523642A (ja) 2011-08-18
US9474800B2 (en) 2016-10-25
JP5663474B2 (ja) 2015-02-04
AU2009248735B2 (en) 2015-08-20
MX2010012587A (es) 2011-05-25
CN102083463A (zh) 2011-06-01
SG191600A1 (en) 2013-07-31
EP2296702A1 (en) 2011-03-23
BRPI0913045A2 (pt) 2017-05-23
CA2724570A1 (en) 2009-11-26
NZ589495A (en) 2012-06-29
US20110171255A1 (en) 2011-07-14
AU2009248735A1 (en) 2009-11-26
RU2010152562A (ru) 2012-06-27
WO2009141434A1 (en) 2009-11-26
KR20110044836A (ko) 2011-05-02
IL209077A0 (en) 2011-01-31
WO2009141434A4 (en) 2010-01-14
CN102083463B (zh) 2017-04-05

Similar Documents

Publication Publication Date Title
IL252561B (en) Antibodies against Siglac-15 polynucleotides encoding them, preparations containing them and their uses
IL215389A0 (en) Pneumococcal vaccine and uses thereof
IL211131A0 (en) Inhbb epitope and vaccines containing the same
IL212240A0 (en) Adjuvant incorporation in immunonanotherapeutics
MY158037A (en) Amphiphilic polysiloxane prepolymers and uses thereof
IL222534A0 (en) Predictive markers useful in the treatment of fragile x syndrome (fxs)
GB0717888D0 (en) Adenoviral vector encoding malaria antigen
ZA201203498B (en) Anti-c4.4a antibodies and uses thereof
ZA200902442B (en) Alphavirus replicon particles as immunological adjuvants
IL209967A0 (en) Cdca1 epitope peptides and vaccines containing the same
IL208312A0 (en) Lentivirus-based immunogenic vectors
IL209077A0 (en) Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant
IL214435A0 (en) Foxm1 peptides and vaccines containing the same
IL209870A0 (en) Mybl2 epitope peptides and vaccines containing the same
ZA201103645B (en) Single-time vaccines
GB0805356D0 (en) Vaccine adjuvant composition
ZA201103667B (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
GB0818065D0 (en) Immunogenic peptides and uses thereof
IL219927A0 (en) Mybl2 peptides and vaccines containing the same
IL215268A0 (en) C6orf167 peptides and vaccines containing the same
GB0917685D0 (en) Antigenic polypeptide
TWI346557B (en) Adjuvant and vaccine includes the same
ZA201104890B (en) Wdrpuh epitope peptides and vaccines containing the same
WO2012140417A3 (en) Combination vaccine against staphyloccal infections
GB201018845D0 (en) The gauntlag